Creating a mouse model for treating aggressive brain tumors with a virus
Official title: Development of murine glioblastoma model for oncolytic HSV therapy
Funded at Augusta University · NIH-10793356 · Data updated 2026-11-12
This study is creating a special mouse model to help researchers find better ways to treat aggressive brain tumors using a virus that can target and kill cancer cells, aiming to improve options for patients facing tough challenges with their condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project start | July 9, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $395,812 |
| NIH project number | 1R61NS128191-01A1 |
| Project ID | NIH-10793356 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with grade IV brain tumors who have limited treatment options.
✕Less likely to help
Patients with non-brain tumors or those who do not have grade IV brain tumors may not benefit from this research.
What this research studies
This research aims to develop a mouse model that mimics grade IV brain tumors, which are known for their poor prognosis. The model will be designed to be sensitive to HSV-1 infection, allowing researchers to test the safety and effectiveness of oncolytic HSV-1 (oHSV) therapies. By using this model, scientists hope to better understand how these viral therapies can be utilized to treat aggressive brain tumors, which currently have limited treatment options. The project addresses the urgent need for alternative therapies in the face of dismal survival rates for patients with these tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with grade IV brain tumors.
How similar studies have gone: Other research has shown promise with similar oncolytic virus therapies in treating various cancers, indicating a potential for success in this novel approach.
Where this research is happening
-
Augusta University
Augusta, United States Active
Researchers
- Principal investigator: Kaur, Balveen — Augusta University
- Study coordinator: Kaur, Balveen
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.